<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31579943</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9896</ISSN><JournalIssue CitedMedium="Internet"><Volume>250</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of pathology</Title><ISOAbbreviation>J Pathol</ISOAbbreviation></Journal><ArticleTitle>Dysregulation of AMPA receptor subunit expression in sporadic ALS post-mortem brain.</ArticleTitle><Pagination><StartPage>67</StartPage><EndPage>78</EndPage><MedlinePgn>67-78</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/path.5351</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is characterised by progressive motor neuron degeneration. Although there are over 40 genes associated with causal monogenetic mutations, the majority of ALS patients are not genetically determined. Causal ALS mutations are being increasingly mechanistically studied, though how these mechanisms converge and diverge between the multiple known familial causes of ALS (fALS) and sporadic forms of ALS (sALS) and furthermore between different neuron types, is poorly understood. One common pathway that is implicated in selective motor neuron death is enhanced &#x3b1;-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPAR)-mediated excitoxicity. Specifically, human in vitro and pathological evidence has linked the C9orf72 repeat expansion mutation to a relative increase in the Ca<sup>2+</sup> -permeable AMPAR population due to AMPAR subunit dysregulation. Here, we provide the first comparative quantitative assessment of the expression profile of AMPAR subunit transcripts, using BaseScope, in post-mortem lower motor neurons (spinal cord, anterior horn), upper motor neurons (motor cortex) and neurons of the pre-frontal cortex in sALS and fALS due to mutations in SOD1 and C9orf72. Our data indicated that AMPAR dysregulation is prominent in lower motor neurons in all ALS cases. However, sALS and mutant C9orf72 cases exhibited GluA1 upregulation whereas mutant SOD1 cases displayed GluA2 down regulation. We also showed that sALS cases exhibited widespread AMPAR dysregulation in the motor and pre-frontal cortex, though the exact identity of the AMPAR subunit being dysregulated was dependent on brain region. In contrast, AMPAR dysregulation in mutant SOD1 and C9orf72 cases was restricted to lower motor neurons only. Our data highlight the complex dysregulation of AMPAR subunit expression that reflects both converging and diverging mechanisms at play between different brain regions and between ALS cohorts. &#xa9; 2019 Authors. Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</AbstractText><CopyrightInformation>&#xa9; 2019 Authors. Journal of Pathology published by John Wiley &amp; Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3337-4079</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livesey</LastName><ForeName>Matthew R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selvaraj</LastName><ForeName>Bhuvaneish T</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Samantha K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100616</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Pathol</MedlineTA><NlmUniqueID>0204634</NlmUniqueID><ISSNLinking>0022-3417</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017470">Receptors, Glutamate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C492973">alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid subtype glutamate receptor, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>P6W5IXV8V9</RegistryNumber><NameOfSubstance UI="C104722">glutamate receptor ionotropic, AMPA 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>TFZ3H25BS1</RegistryNumber><NameOfSubstance UI="C097222">glutamate receptor ionotropic, AMPA 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="N">Autopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017470" MajorTopicYN="N">Receptors, Glutamate</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">AMPAR</Keyword><Keyword MajorTopicYN="N">BaseScope</Keyword><Keyword MajorTopicYN="N">C9orf72</Keyword><Keyword MajorTopicYN="N">RNA</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">neuron</Keyword><Keyword MajorTopicYN="N">post-mortem</Keyword><Keyword MajorTopicYN="N">sporadic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31579943</ArticleId><ArticleId IdType="pmc">PMC6973025</ArticleId><ArticleId IdType="doi">10.1002/path.5351</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Renton AE, Majounie E, Waite A, et al A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 2011; 72: 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Black HA, Leighton DJ, Cleary EM, et al Genetic epidemiology of motor neuron disease&#x2010;associated variants in the Scottish population. Neurobiol Aging 2017; 51: 178.e11&#x2013;178.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5302213</ArticleId><ArticleId IdType="pubmed">28089114</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Chen HJ, Shaw CE. TDP&#x2010;43 proteinopathy and ALS: insights into disease mechanisms and therapeutic targets. Neurotherapeutics 2015; 12: 352&#x2013;363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404432</ArticleId><ArticleId IdType="pubmed">25652699</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW, et al From genes to mechanism. Nature 2016; 539: 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Isaacs AM. C9orf72&#x2010;mediated ALS and FTD: multiple pathways to disease. Nat Rev Neurol 2018; 14: 544&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417666</ArticleId><ArticleId IdType="pubmed">30120348</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001; 2: 806&#x2013;819.</Citation><ArticleIdList><ArticleId IdType="pubmed">11715057</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynelis SF, Wollmuth LP, McBain CJ, et al Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev 2010; 62: 405&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2964903</ArticleId><ArticleId IdType="pubmed">20716669</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TL, Day NC, Ince PG, et al Calcium&#x2010;permeable alpha&#x2010;amino&#x2010;3&#x2010;hydroxy&#x2010;5&#x2010;methyl&#x2010;4&#x2010;isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1997; 42: 200&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">9266730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Kwak S, Sun H, et al Human spinal motoneurons express low relative abundance of GluR2 mRNA: an implication for excitotoxicity in ALS. J Neurochem 2003; 85: 680&#x2013;689.</Citation><ArticleIdList><ArticleId IdType="pubmed">12694394</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Ito K, Sun H, et al Glutamate receptors: RNA editing and death of motor neurons. Nature 2004; 427: 801.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985749</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Braeken D, Callewaert G, et al GluR2 deficiency accelerates motor neuron degeneration in a mouse model of amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2005; 64: 605&#x2013;612.</Citation><ArticleIdList><ArticleId IdType="pubmed">16042312</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L, Van Damme P, Bogaert E, et al The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochim Biophys Acta 2006; 1762: 1068&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">16806844</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Bogaert E, Dewil M, et al Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A 2007; 104: 14825&#x2013;14830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1976195</ArticleId><ArticleId IdType="pubmed">17804792</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Lin S, Staats KA, et al Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. Nat Med 2018; 24: 313&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112156</ArticleId><ArticleId IdType="pubmed">29400714</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj BT, Livesey MR, Zhao C, et al C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+&#x2010;permeable AMPA receptor&#x2010;mediated excitotoxicity. Nat Commun 2018; 9: 347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, et al Pathological TDP&#x2010;43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol 2007; 61: 427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf6;lle TR, Berthele A, Zieglg&#xe4;nsberger W, et al The differential expression of 16 NMDA and non&#x2010;NMDA receptor subunits in the rat spinal cord and in periaqueductal gray. J Neurosci 1993; 13: 5009&#x2013;5028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6576409</ArticleId><ArticleId IdType="pubmed">8254358</ArticleId></ArticleIdList></Reference><Reference><Citation>Rekling JC, Funk GD, Bayliss DA, et al Synaptic control of motoneuronal excitability. Physiol Rev 2000; 80: 767&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4764886</ArticleId><ArticleId IdType="pubmed">10747207</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathol 2014; 127: 347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwak S, Hideyama T, Yamashita T, et al AMPA receptor&#x2010;mediated neuronal death in sporadic ALS. Neuropathology 2010; 30: 182&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">20102521</ArticleId></ArticleIdList></Reference><Reference><Citation>Pick JE, Ziff EB. Regulation of AMPA receptor trafficking and exit from the endoplasmic reticulum. Mol Cell Neurosci 2018; 91: 3&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6128777</ArticleId><ArticleId IdType="pubmed">29545119</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieri M, Gaetti C, Spalloni A, et al Alpha&#x2010;Amino&#x2010;3&#x2010;hydroxy&#x2010;5&#x2010;methyl&#x2010;isoxazole&#x2010;4&#x2010;propionate receptors in spinal cord motor neurons are altered in transgenic mice overexpressing human Cu, Zn superoxide dismutase (Gly93&#x2192;Ala) mutation. Neuroscience 2003; 122: 47&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">14596848</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateno M, Sadakata H, Tanaka M, et al Calcium&#x2010;permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet 2004; 13: 2183&#x2013;2196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuner R, Groom AJ, Bresink I, et al Late&#x2010;onset motoneuron disease caused by a functionally modified AMPA receptor subunit. Proc Natl Acad Sci U S A 2005; 102: 5826&#x2013;5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC556301</ArticleId><ArticleId IdType="pubmed">15827116</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri S, Krampfl K, Hashemi F, et al The mRNA expression of AMPA type glutamate receptors in the primary motor cortex of patients with amyotrophic lateral sclerosis: an in situ hybridization study. Neurosci Lett 2004; 360: 170&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">15082160</ArticleId></ArticleIdList></Reference><Reference><Citation>Camerino GM, Fonzino A, Conte E, et al Elucidating the contribution of skeletal muscle ion channels to amyotrophic lateral sclerosis in search of new therapeutic options. Sci Rep 2019; 9: 3185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6395744</ArticleId><ArticleId IdType="pubmed">30816241</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S, Alsop E, Lorenzini I, et al ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72&#x2010;mediated ALS/FTD. Acta Neuropathol 2019; 138: 49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750285</ArticleId><ArticleId IdType="pubmed">30945056</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>